Regeneus (ASX:RGS) flagship asset is a patented off-the-shelf stem cell technology for the treatment of knee osteoarthritis and other inflammatory conditions.
The company has entered licensing agreements in Japan.
Japan, with its rapidly ageing population, is committing itself to world-leading reform and investment in the field of regenerative medicine.
Find out more from John Martin at Proactive's CEO Sessions.
Click below to register by email
- Sydney: Wednesday 14th June.
- Melbourne: Thursday 15th June.
- Email Pauline here.
- Call office on (02) 9280 0700.
Presenter list
- Regeneus (ASX:RGS): MD John Martin
- Tlou Energy (ASX:TOU): MD & CEO Tony Gilby
- AuKing Mining (ASX:AKN): MD Paul Williams
- XTEK (ASX:XTE): MD Philippe Odouard
- Pioneer Resources (ASX:PIO): MD David Crook